Abbott Laboratories (ABT)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 41,950,000 | 41,217,000 | 40,725,000 | 40,326,000 | 40,109,000 | 39,959,000 | 40,226,000 | 41,505,000 | 43,653,000 | 45,030,000 | 45,548,000 | 44,514,000 | 43,075,000 | 42,308,000 | 40,233,000 | 37,338,000 | 34,608,000 | 32,221,000 | 31,444,000 | 32,095,000 |
Total current assets | US$ in thousands | 23,656,000 | 23,802,000 | 23,119,000 | 22,376,000 | 22,670,000 | 22,664,000 | 23,505,000 | 25,224,000 | 25,224,000 | 24,845,000 | 24,956,000 | 23,429,000 | 24,239,000 | 23,492,000 | 22,627,000 | 21,817,000 | 20,441,000 | 17,390,000 | 17,221,000 | 15,498,000 |
Total current liabilities | US$ in thousands | 14,157,000 | 14,902,000 | 13,760,000 | 14,021,000 | 13,841,000 | 13,042,000 | 14,350,000 | 15,489,000 | 15,489,000 | 13,365,000 | 12,392,000 | 12,647,000 | 13,105,000 | 12,867,000 | 12,614,000 | 12,462,000 | 11,907,000 | 10,257,000 | 10,959,000 | 10,808,000 |
Working capital turnover | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.26 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | 4.06 | 4.52 | 5.02 | 6.84 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $41,950,000K ÷ ($23,656,000K – $14,157,000K)
= 4.42
The working capital turnover of Abbott Laboratories has shown a decreasing trend over the past few years, indicating a potential inefficiency in managing its working capital. The ratio, which measures the company's ability to generate revenue relative to its working capital, has decreased from 6.84 as of March 31, 2020, to 4.42 as of December 31, 2024.
A declining working capital turnover could suggest difficulties in efficiently utilizing the company's current assets to support its operations and sales. This decrease may be a cause for concern as it implies that Abbott Laboratories may be taking longer to convert its working capital into sales revenue.
Management should closely monitor and analyze the components of working capital, such as inventory, accounts receivable, and accounts payable, to identify potential inefficiencies and implement strategies to improve working capital turnover and enhance overall operational efficiency.
Peer comparison
Dec 31, 2024
See also:
Abbott Laboratories Working Capital Turnover (Quarterly Data)